Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 159-163

  Kruck, Stephan ^a   Bedke, Jens ^a   Hennenlotter, Jörg ^a   Ohneseit, Petra A ^a   Kuehs, Ursula ^a   Senger, Erika ^a   Sievert, Karl Dietrich ^a   Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Mammalian target of rapamycin; Phosphorylated mTOR; Phosphorylation; Renal cell carcinoma; Targeted therapy

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; COHORT STUDIES; DENSITOMETRY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 76049097260     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000617     Document Type: Article

References (20)

1. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ and Sinescu IC: Renal cell carcinoma guideline. Eur Urol 51: 1502-1510, 2007.
2. Amato RJ, Jac J, Giessinger S, Saxena S and Willis JP: A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115: 2438-2446, 2009.
3. Kruck S, Kuczyk MA, Gakis G, Kramer MW, Stenzl A and Merseburger AS: Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update. Rev Recent Clin Trials 3: 212-216, 2008.
4. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L and Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
5. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
6. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C and Ratain MJ: A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15: 1428-1434, 2009.
7. Kapoor A: Inhibition of mtor in kidney cancer. Curr Oncol 16 (Suppl 1): S33-S39, 2009.
8. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
9. Chiang GG and Abraham RT: Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280: 25485-25490, 2005.
10. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM and Abraham RT: A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60: 3504-3513, 2000.
11. Eble JN: Pathology and genetics of tumours of the urinary system and male genital organs. In: World Health Organisation Classification of Tumours. Eble JN, Sauter G and Epstein JI (eds). IARC Press, Lyons, p7, 2004.
12. Sobin LH: TNM Classification of malignant tumours. In: International Union Against Cancer (UICC) 6th edition. Sobin LH (ed). New York, pp193-195, 2002,
13. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
14. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
15. Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW and Sesterhenn IA: Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 10: 223-228, 2003.
16. Theodorescu D, Broder SR, Boyd JC, Mills SE and Frierson HF Jr: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80: 2109-2119, 1997.
17. Hennenlotter J, Ohneseit PA, Simon P, Merseburger AS, Serth J, Kuehs U, Kramer M, Hartmann JT, Stenzl A and Kuczyk MA: PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas - implications for Akt activation. Oncol Rep 19: 1141-1147, 2008.
18. Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A and Kuczyk MA: An update on the medical therapy of advanced metastatic renal cell carcinoma. Scand J Urol Nephrol 42: 501-506, 2008.
19. Long X, Lin Y, Ortiz-Vega S, Yonezawa K and Avruch J: Rheb binds and regulates the mTOR kinase. Curr Biol 15: 702-713, 2005.
20. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS and Figlin RA: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109: 2257-2267, 2007.